Silver Book Fact

Shingles vaccine reduces incidence by >50%

Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.

Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. NEJM. 2005; 352(22): 2271-84. http://www.nejm.org/doi/full/10.1056/NEJMoa051016

Reference

Title
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
NEJM
Publication Date
2005
Authors
Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group
Volume & Issue
Volume 352, Issue 22
Pages
2271-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Shingles vaccine would reduce healthcare use
    Use of the shingles vaccine in immunocompetent adults could eliminate more than 300,000 outpatient visits, 375,000 prescriptions, 9,700 emergency room visits, and 10,000 hospitalizations.  
  • Reduction of central-line infections saved ~ 1,800 lives and $280 million
    Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.  
  • Economic value from flu vaccine in elderly
    As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest…  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • Over 8 years infection control practices saved ~27,000 lives and $1.8 billion
    Infection control practices saved an estimated 27,000 lives and $1.8 billion in medical costs between 2001 and 2009.